Use of Minimal Residual Disease Assessment to Redefine Induction Failure in Pediatric Acute Lymphoblastic Leukemia.

Use of Minimal Residual Disease Assessment to Redefine Induction Failure in Pediatric Acute Lymphoblastic Leukemia.

Purpose<br/> Our aim was to determine the role of end-of-induction (EOI) minimal residual disease (MRD) assessment in the identification and stratification of induction failure in patients with pediatric acute lymphoblastic leukemia (ALL) and to identify genetic abnormalities that drive...

Volledige beschrijving

Bibliografische gegevens
Hoofdauteurs:	O'Connor, D, Moorman, A, Wade, R, Hancock, J, Tan, R, Bartram, J, Moppett, J, Schwab, C, Patrick, K, Harrison, C, Hough, R, Goulden, N, Vora, A, Samarasinghe, S
Formaat:	Journal article
Taal:	English
Gepubliceerd in:	American Society of Clinical Oncology 2017

Gelijkaardige items

Genotype-specific MRD interpretation improves stratification in paediatric acute lymphoblastic leukaemia
door: O'Connor, D, et al.
Gepubliceerd in: (2017)

Infection-related mortality in children with acute lymphoblastic leukemia: an analysis of infectious deaths on UKALL2003.
door: O'Connor, D, et al.
Gepubliceerd in: (2014)

Augmented post-remission therapy for a minimal residual disease-defined high-risk subgroup of children and young people with clinical standard-risk and intermediate-risk acute lymphoblastic leukaemia (UKALL 2003): a randomised controlled trial.
door: Vora, A, et al.
Gepubliceerd in: (2014)

Augmented post-remission therapy for a minimal residual disease-defined high-risk subgroup of children and young people with clinical standard-risk and intermediate-risk acute lymphoblastic leukaemia (UKALL 2003): A randomised controlled trial
door: Vora, A, et al.
Gepubliceerd in: (2014)

Cytogenetic-specific heterogeneity in the kinetics of minimal residual disease (MIRD) clearance in childhood lymphoblastic leukaemia (ALL)
door: Moorman, A, et al.
Gepubliceerd in: (2008)

Treatment reduction for children and young adults with low-risk acute lymphoblastic leukaemia defined by minimal residual disease (UKALL 2003): a randomised controlled trial.
door: Vora, A, et al.
Gepubliceerd in: (2013)

Treatment reduction for children and young adults with low-risk acute lymphoblastic leukaemia defined by minimal residual disease (UKALL 2003): a randomised controlled trial
door: Vora, A, et al.
Gepubliceerd in: (2013)

Down Syndrome is a significant risk factor for infectious deaths in childhood acute lymphoblastic leukaemia: a retrospective analysis of the infectious deaths on UKALL 2003
door: O'Connor, D, et al.
Gepubliceerd in: (2014)

A novel integrated cytogenetic and genomic classification refines risk stratification in pediatric acute lymphoblastic leukemia.
door: Moorman, A, et al.
Gepubliceerd in: (2014)

Cytogenetic-specific heterogeneity in the kinetics of minimal residual disease (MRD) clearance in childhood acute lymphoblastic leukaemia (ALL)
door: Moorman, A, et al.
Gepubliceerd in: (2007)

Outcome of Down syndrome associated acute lymphoblastic leukaemia treated on a contemporary protocol.
door: Patrick, K, et al.
Gepubliceerd in: (2014)

Outcome of Down syndrome associated acute lymphoblastic leukaemia treated on a contemporary protocol
door: Patrick, K, et al.
Gepubliceerd in: (2014)

Risk-directed treatment intensification significantly reduces the risk of relapse among children and adolescents with acute lymphoblastic leukemia and intrachromosomal amplification of chromosome 21: a comparison of the MRC ALL97/99 and UKALL2003 trials.
door: Moorman, A, et al.
Gepubliceerd in: (2013)

Outcome for children and young people with Early T-cell precursor acute lymphoblastic leukaemia treated on a contemporary protocol, UKALL 2003
door: Patrick, K, et al.
Gepubliceerd in: (2014)

Outcome for children and young people with Early T-cell precursor acute lymphoblastic leukaemia treated on a contemporary protocol, UKALL 2003.
door: Patrick, K, et al.
Gepubliceerd in: (2014)

UKALL 2003, A Randomised Trial Investigating Treatment Intensification for Children and Young Adults with Minimal Residual Disease Defined High Risk Acute Lymphoblastic Leukaema
door: Vora, A, et al.
Gepubliceerd in: (2012)

Impact of NOTCH1/FBXW7 mutations on outcome in pediatric T-cell acute lymphoblastic leukemia patients treated on the MRC UKALL 2003 trial.
door: Jenkinson, S, et al.
Gepubliceerd in: (2013)

Incidence and outcome of pancreatitis in children and young adults with acute lymphoblastic leukaemia treated on a contemporary protocol, UKALL 2003
door: Samarasinghe, S, et al.
Gepubliceerd in: (2013)

Incidence and outcome of pancreatitis in children and young adults with acute lymphoblastic leukaemia treated on a contemporary protocol, UKALL 2003.
door: Samarasinghe, S, et al.
Gepubliceerd in: (2013)

Prognostic impact of the absence of biallelic deletion at the TRG locus for pediatric patients with T-cell acute lymphoblastic leukemia treated on the Medical Research Council UK Acute Lymphoblastic Leukemia 2003 trial
door: Nadine Farah, et al.
Gepubliceerd in: (2018-07-01)

Post-Remission MRD Kinetics in Children with Acute Lymphoblastic Leukaemia Receiving Augmented BFM Consolidation Compared with Other Regimens Results of the Medical Research Council Trial UKALL2003.
door: Cutting, R, et al.
Gepubliceerd in: (2008)

IGH@ translocations are prevalent in teenagers and young adults with acute lymphoblastic leukemia and are associated with a poor outcome.
door: Russell, L, et al.
Gepubliceerd in: (2014)

Post-remission MRD kinetics in children with acute lymphoblastic leukaemia receiving augmented BFM consolidation compared with other regimens: update of results of the Medical Research Council Trial UKALL2003
door: Cutting, R, et al.
Gepubliceerd in: (2009)

Improved Outcome for Children and Young Adults with T-Cell Acute Lymphoblastic Leukaemia (ALL): Results of the United Kingdom Medical Research Council (MRC) Trial UKALL 2003
door: Vora, A, et al.
Gepubliceerd in: (2008)

Efficacy and Toxicity of Pegylated Asparaginase in the Treatment of Children and Young Adults with Acute Lymphoblastic Leukaemia: Results of the United Kingdom Medical Research Council (MRC) Trial UKALL 2003
door: Vora, A, et al.
Gepubliceerd in: (2008)

Incidence and Outcome of Osteonecrosis in Children and Young Adults with Acute Lymphoblastic Leukaemia Treated on a Dexamethasone Containing Protocol: Results of the Medical Research Council UK Trial ALL 2003
door: Vora, A, et al.
Gepubliceerd in: (2008)

UKALL 2003, A Randomised Trial Investigating Treatment Reduction for Children and Young Adults with Minimal Residual Disease Defined Low Risk Acute Lymphoblastic Leukaemia
door: Vora, A, et al.
Gepubliceerd in: (2010)

UKALL 2003, A Randomised Trial Investigating Treatment Reduction for Children and Young Adults with Minimal Residual Disease Defined Low Risk Acute Lymphoblastic Leukaemia
door: Vora, A, et al.
Gepubliceerd in: (2010)

UKALL 2003, A Randomised Trial Investigating Treatment Reduction for Children and Young Adults with Minimal Residual Disease Defined Low Risk Acute Lymphoblastic Leukaemia
door: Vora, A, et al.
Gepubliceerd in: (2010)

Profile of Steroid Toxicity During Maintenance Treatment in Teenage and Young Adult (TYA) Patients with Acute Lymphoblastic Leukaemia (ALL)
door: Tomlins, J, et al.
Gepubliceerd in: (2012)

Variables affecting kinetics of minimal residual disease clearance in children with lymphoblastic leukaemia; Results of the United Kingdom Medical Research Council (UK MRC) protocols ALL97, ALL97/99 and ALL2003.
door: Vora, A, et al.
Gepubliceerd in: (2005)

Polymorphism in the PAI-1 (SERPINE1) gene and the risk of osteonecrosis in children with acute lymphoblastic leukemia
door: Bond, J, et al.
Gepubliceerd in: (2011)

Polymorphism in the PAI-1 (SERPINE1) gene and the risk of osteonecrosis in children with acute lymphoblastic leukemia.
door: Bond, J, et al.
Gepubliceerd in: (2011)

Delineation of Risk Factors in Paediatric Acute Lymphoblastic Leukaemia with Favourable Cytogenetics
door: Moorman, A, et al.
Gepubliceerd in: (2012)

BTG1 deletions do not predict outcome in Down syndrome acute lymphoblastic leukemia.
door: Buitenkamp, T, et al.
Gepubliceerd in: (2013)

BTG1 deletions do not predict outcome in Down syndrome acute lymphoblastic leukemia
door: Buitenkamp, T, et al.
Gepubliceerd in: (2013)

Advances in acute lymphoblastic leukemia genomics
door: Christine J. Harrison, et al.
Gepubliceerd in: (2018-06-01)

Presence of mutations in the NOTCH1 signalling pathway has a beneficial impact on outcome in paediatric T-ALL patients treated on the MRC UKALL2003 trial
door: Jenkinson, S, et al.
Gepubliceerd in: (2012)

Prognosis of children with acute lymphoblastic leukemia (ALL) and intrachromosomal amplification of chromosome 21 (iAMP21).
door: Moorman, A, et al.
Gepubliceerd in: (2007)

Advances in B-cell Precursor Acute Lymphoblastic Leukemia Genomics
door: Claire Schwab, et al.
Gepubliceerd in: (2018-08-01)